RUTHERFORD, N.J., Nov. 18, 2013 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or the “Company”), an emerging leader in DNA-based diagnostics, announced that its proprietary DNA-based test for cervical cancer, FHACT™, has received regulatory approval from the Clinical Laboratory Improvement Amendments (CLIA) as a Laboratory Developed Test (LDT). The test will be made available to help in the triaging and decision-making associated with the roughly 3.5 million abnormal Pap smears in the U.S. each year in order to diagnose and manage cervical cancer. CGI’s FHACT™ test provides genomic information directly from the abnormal Pap smear sample and does not require additional office visits.
Help employers find you! Check out all the jobs and post your resume.
